Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Name of entity Race Oncology Limited ABN 61 149 318 749 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Chris Ntoumenopoulos Date of last notice 22 November 2017 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Nature of indirect interest (including registered holder) 1. 2. 3. 2. Direct Indirect Indirect Sobol Capital Pty Ltd <BOC Investment A/C> – director related entity Mr Chris Ntoumenopoulos & Mr Leo Ntoumenopoulos <Ntoumenopoulos S/F A/C> - sole beneficiary Note: Provide details of the circumstances giving rise to the relevant interest. 3. Date of change 8 February 2019 No. of securities held prior to change Class 2. 506,250 Ordinary Shares 1,000,000 options exercisable 22 November 2019 1,000,000 options exercisable 22 November 2019 3. 100,000 Ordinary Shares Ordinary Shares Number acquired 53,847 Number disposed - Value/Consideration includes brokerage/gst Nil at $0.49, expiring at $0.65, expiring Note: If consideration is non-cash, provide details and estimated valuation + See chapter 19 for defined terms. Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back 1. 53,847 Ordinary Shares 2. 506,250 Ordinary Shares 1,000,000 options exercisable 22 November 2019 1,000,000 options exercisable 22 November 2019 3. 100,000 Ordinary Shares at $0.49, expiring at $0.65, expiring Shares acquired by off-market transfer as part of an in specie distribution of shares held by Update Pharma Inc, a company in which Chris Ntoumenopoulos holds a minority interest. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to N/A which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed No. above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided? + See chapter 19 for defined terms. Appendix 3Y Page 2